62
Participants
Start Date
May 1, 2024
Primary Completion Date
March 26, 2025
Study Completion Date
August 12, 2025
Camoteskimab
Drug Product
Placebo
Inactive substance
Paddington Testing Co. Inc, Philadelphia
ObjectiveHealth-The Skin Surgery Center for Clinical Research, Winston-Salem
M3 Wake Research, Inc., Raleigh
Michigan Dermatology Institute, Waterford
D&H National Research Centers, Inc., Miami
Avita Clinical Research - Dermatology, Tampa
Renaissance Research and Medical Group, Cape Coral
Skin Sciences, PLLC, Louisville
Owensboro Dermatology Associates, Owensboro
Dawes Fretzin Clinical Research, Indianapolis
Revival Research Institute, Troy
Somerset Skin Centre, Troy
Sneeze, Wheeze & Itch Associates, LLC, Normal
Advanced Dermatology and Skin Cancer Center - Saint Joseph, Saint Joseph
Skin Specialists PC, Omaha
Central Sooner Research, Oklahoma City
Unity Clinical Research - Dermatology, Oklahoma City
Rodgers Dermatology, Frisco
Center for Clinical Studies, Houston
Clinical Trial Network, Houston
Medical Dermatology Specialists, PC/US Dermatology Partners, Phoenix
California Allergy and Asthma Medical Group, Los Angeles
University of California Los Angeles Dermatology, Los Angeles
Clinical Sciences Institute, Santa Monica
Amicis Research Center (Northridge), Northridge
California Dermatology & Clinical Research Institute, Encinitas
VASDHS - Veterans Affairs San Diego Medical Center, San Diego
First OC Dermatology Research, Inc., Fountain Valley
Cura Clinical Research, Oxnard
Center for Dermatology Clinical Research, Inc., Fremont
Youthful Image, Edmonton
Rejuvenation Dermatology Clinic Edmonton South, Edmonton
Kingsway Clinical Research, Etobicoke
Clinique Medicale Saint-Louis, Québec
Clinique Dermatologique de Sherbrooke, Sherbrooke
Lead Sponsor
Apollo Therapeutics Ltd
INDUSTRY